Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Tyrosine Vs Tacrolimus With NB-UVB in Vitiligo

NCT: NCT07532330 · ACTIVE_NOT_RECRUITING

NCT IDNCT07532330
StatusACTIVE_NOT_RECRUITING
Start Date2025-08-01
Completion2026-04-10

Brief Summary

The goal of this clinical trial is to learn if adding topical tacrolimus or topical tyrosine to narrowband UVB phototherapy works to treat vitiligo in adults. It will also learn about the safety of both combinations. The main questions it aims to answer are: Which combination (UVB + tacrolimus or UVB + tyrosine) leads to greater skin repigmentation (color return) after 3 months of treatment? What side effects do participants experience with each combination? Researchers will compare three groups: UVB + tacrolimus, UVB + tyrosine, and UVB only to see which is more effective and safer. Participants will: Receive narrowband UVB phototherapy sessions two times per week at minimal erythema dose Apply either topical tacrolimus or topical tyrosine to their vitiligo patches twice daily Visit the clinic every one month for skin examination and photography Report any side effects or skin reactions

Frequently Asked Questions

What is Tyrosine Vs Tacrolimus With NB-UVB in Vitiligo?

Tyrosine Vs Tacrolimus With NB-UVB in Vitiligo is a clinical trial registered under NCT07532330. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT07532330?

The current status of NCT07532330 (Tyrosine Vs Tacrolimus With NB-UVB in Vitiligo) is: ACTIVE_NOT_RECRUITING.

When did Tyrosine Vs Tacrolimus With NB-UVB in Vitiligo start?

Tyrosine Vs Tacrolimus With NB-UVB in Vitiligo started on 2025-08-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.